Mitoxantrone Dihydrochloride

References

• Mitoxantrone modulates a heparan sulfate‑spike complex to inhibit SARS‑CoV‑2 infection
  • Q. Zhang, P. Radvak, J. Lee, Y. Xu, V. Cao‑Dao, M. Xu, W. Zheng, C.Z. Chen, H. Xie, Y. Ye, Sci. Rep. 2022, 12, 6294.
• Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone
  • S.E. Altmann, A.L. Smith, J. Dyall, R.F. Johnson, L.E. Dodd, P.B. Jahrling, J. Paragas, J.E. Blaney, Antiviral Res. 2012, 93, 305.
• Developing a Dynamic Pharmacophore Model for HIV-1 Integrase
  • H.A. Carlson, K.M. Masukawa, K. Rubins, F.D. Bushman, W.L. Jorgensen, R.D. Lins, J.M. Briggs, J.A. McCammon, J. Med. Chem. 2000, 43, 2100.


Anwendung
Mitochondria research

Reference

• Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells
  • J.Kluza, P. Marchetti, M.-A. Gallego, S. Lancel, C. Fournier, A. Loyens, J.-C. Beauvillain, C. Bailly, Oncogene 2004, 23, 7018.


Anwendung
Mitoxantrone Dihydrochloride: A Synthetic Anthracycline Antitumor Agent with Improved Tolerability
Mitoxantrone [M3133] and its dihydrochloride are synthetic anthracycline antitumor agents that are structurally similar to doxorubicin hydrochloride [D4193] and daunorubicin hydrochloride [D4532]. Mitoxantrones intercalate into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. .Mitoxantrones also inhibit DNA repair by inhibiting topoisomerase II which results in fragmentation of DNA. Mitoxantrones display an improved tolerability profile compared with doxorubicin and other anthracyclines, but cross-resistance with the anthracyclines has been demonstrated. (The product is for research purpose only.)

References

• Experimental antitumor activity of aminoanthraquinones
  • R. K. Johnson, R. K. Zee-Cheng, W. W. Lee, E. M. Acton, D. W. Henry, C. C. Cheng, Cancer Treat. Rep. 1979, 63, 425.
• Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones
  • K. C. Murdock, R. G. Child, P. F. Fabio, R. D. Angier, R. E. Wallace, F. E. Durr, R. V. Citarella, J. Med. Chem. 1979, 22, 1024.
• Mechanism of Action of Topoisomerase II-Targeted Antineoplastic Drugs
  • N. Osheroff, A. H. Corbett, M. J. Robinson, Adv. Pharmacol. 1994, 29B, 105.
• Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer
  • D. Faulds, J. A. Balfour, P. Chrisp, H. D. Langtry, Drugs 1991, 41, 400.
• Mechanism of action of mitoxantrone (a review)
  • E. J. Fox, Neurology 2004, 63, S15.
• HPLC analysis of mitoxantrone in mouse plasma and tissues: Application in a pharmacokinetic study
  • G. An, M. E. Morris, J. Pharm. Biomed. Anal. 2010, 51, 750.
• Mitoxantrone hydrochloride (a review on the description, synthesis, physical properties, stability, pharmacology, and detection)
  • J. H. Beijnen, A. Bult, W. J. M. Underberg, Anal. Profiles Drug Subst. 1988, 17, 221.